Literature DB >> 22962342

GREVE: Genomic Recurrent Event ViEwer to assist the identification of patterns across individual cancer samples.

Jean-Baptiste Cazier1, Chris C Holmes, John Broxholme.   

Abstract

SUMMARY: GREVE has been developed to assist with the identification of recurrent genomic aberrations across cancer samples. The exact characterization of such aberrations remains a challenge despite the availability of increasing amount of data, from SNParray to next-generation sequencing. Furthermore, genomic aberrations in cancer are especially difficult to handle because they are, by nature, unique to the patients. However, their recurrence in specific regions of the genome has been shown to reflect their relevance in the development of tumors. GREVE makes use of previously characterized events to identify such regions and focus any further analysis. AVAILABILITY: GREVE is available through a web interface and open-source application (http://www.well.ox.ac.uk/GREVE).

Entities:  

Mesh:

Year:  2012        PMID: 22962342      PMCID: PMC3496338          DOI: 10.1093/bioinformatics/bts547

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


1 INTRODUCTION

Genomic aberrations have been the subject of much interest in the past decade with variable degrees of success. Two categories have to be distinguished: exactly matching germline and unique, often somatic, aberrations. There has been much effort to identify and catalogue the former in order to treat them like regular markers such as SNPs (Iafrate ). The first difficulty lies in the exact characterization of the breakpoints. Furthermore, such inventory is impossible for somatic events that are by definition unique. Still, the recurrence of overlapping regions can indicate a key controlling area, e.g. a small deletion on 9p in adolescent acute lymphoblastic leukemia (Paulsson ). Current approaches are essentially based on either the integration into a general-purpose browser to provide context, but no measure of overlap, or the creation of a heatmap where the copy number itself is used as a metric across all types of events to characterize the recurrence (Cancer Genome WorkBench, https://cgwb.nci.nih.gov/cgi-bin/heatmap; Mermel ). This single continuous value is then used to construct a score at every location. GREVE is designed to look into further details by allowing the user to define further subgroups such as copy neutral LOH that would be ignored otherwise. Furthermore, GREVE provides a highly configurable interface and specific statistics on recurrent events. GREVE has been successfully used in numerous cancer studies where the cohort size varied from a handful (Langemeijer ; Olsson ; Paulsson ) to hundreds (Gupta ; O’Shea ). Highly flexible, GREVE provides the ability to statistically explore a given dataset and to present results in a ready-to-publish format.

2 FEATURES

The purpose of GREVE is to enable a flexible view of aberrations across the genome, or per chromosome, and score their recurrence. Therefore, the default usage is very simple with the input of the sole list of events being sufficient, while it is highly configurable with further optional input to help the inspection.

2.1 Key features

GREVE transforms a list of events into a genomic representation, summarizes and scores their recurrence across samples: Read flat or Excel input files containing a list of event per individual and type, with build 35, 36 or 37 location (Fig. 1b).
Fig. 1.

Usage of GREVE where (a) pre-processing from any source generates a list of events to be used as (b) input together with the optional DGV, Configuration and Gene file. This can generate several output (c): two types of genome-wide views (sorted by aberration type or individual), chromosome view with overlap, gene and labels, as well as the detailed list of overlapping events with corresponding counts and statistics

Plot all events genome-wide and per chromosome with cytobands. The views can either sort all the events or overlay them with a fixed set of individuals (Fig. 1c). Calculate, tabulate and plot recurrence within any given type of events (e.g. Gain, Loss and LOH), score each overlapping segment across multiple statistics (Fig. 1c). Generate publication-ready figures in several graphical formats (EPS, PDF, PNG, JPG or TIFF; Fig. 1c). Inclusion of key genes on the per-chromosome plot as given in a separate list or known CNV from the Database of Genomic Variants (Iafrate ). Usage of GREVE where (a) pre-processing from any source generates a list of events to be used as (b) input together with the optional DGV, Configuration and Gene file. This can generate several output (c): two types of genome-wide views (sorted by aberration type or individual), chromosome view with overlap, gene and labels, as well as the detailed list of overlapping events with corresponding counts and statistics

2.2 Formatting features

Because each study will have varying numbers of individuals and events, the default layout may not be optimal. All positions and colors are available in an optional configuration file. Size and color choice for each aberration type. Distance between successive events and chromosomes. Highlight aberration of certain type (default ‘LOH’). Merger of exactly matching events into a larger block.

3 IMPLEMENTATION

The GREVE web front end is implemented in HTML/PHP as a wrapper around the Python (van Rossum and Drake, 2001) script engine running on the web server. It requires ImageMagick software (Still, 2005) for figure format conversion from the default Encapsulated PostScript format. The Poisson binomial test is implemented as a wrapper around the Poibin R-package (Hong ). The web interface allows the upload of all necessary files and a convenient way to select filters and options. It then outputs ready-to-publish figures as well as overlapping details. Examples and frequently asked questions are available on the website. All the options in the engine software are available through the graphical interface. However, to allow batch processing and further analysis, the source code is available on the website. This should allow specific extensions to match any given project such as subgrouping of individuals (Purdie , 2010). The large demo analysis with 709 events across 30 samples takes 7 s on an AMD64 3.0 GHz processor with 64 Gb of RAM to process with overlaps and scores.

3.1 Input files

Only the list of events with corresponding sample labels and type is necessary to run GREVE. It can be generated from the output of various aberration callers from SNP or CGH array as well as sequencing data with eventual post-processing (Fig. 1a and b). Further optional flags, filters and files can be provided to add information or tailor the presentation: The list of events with location, sample labels and type of aberration. An optional gene list with name and position. An optional configuration file allows further tailoring of the figures without the need to modify the program.

3.2 Output

The result of the analysis is composed of figures and tables (Fig. 1c): Genome-wide and chromosome view of the events in all formats. Details of the overlap of events across each chromosome are available directly in the interface as a table or in a separate file. The counts and proportion of overlap reflect the comparison to a control set where no somatic event would be expected. The Poisson binomial P-value tests the probability of a type occurring at the same location depending on the individual proportion on a chromosome (C_P) or genome-wide (GW_P).
  10 in total

1.  Detection of large-scale variation in the human genome.

Authors:  A John Iafrate; Lars Feuk; Miguel N Rivera; Marc L Listewnik; Patricia K Donahoe; Ying Qi; Stephen W Scherer; Charles Lee
Journal:  Nat Genet       Date:  2004-08-01       Impact factor: 38.330

2.  Genetic landscape of high hyperdiploid childhood acute lymphoblastic leukemia.

Authors:  Kajsa Paulsson; Erik Forestier; Henrik Lilljebjörn; Jesper Heldrup; Mikael Behrendtz; Bryan D Young; Bertil Johansson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

3.  Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation.

Authors:  Derville O'Shea; Ciarán O'Riain; Manu Gupta; Rachel Waters; Youwen Yang; David Wrench; John Gribben; Andreas Rosenwald; German Ott; Lisa M Rimsza; Harald Holte; Jean-Baptiste Cazier; Nathalie A Johnson; Elias Campo; Wing C Chan; Randy D Gascoyne; Bryan D Young; Louis M Staudt; T Andrew Lister; Jude Fitzgibbon
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

4.  Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: Unexpected similarities with pediatric disease.

Authors:  Kajsa Paulsson; Jean-Baptiste Cazier; Finlay Macdougall; Jane Stevens; Irina Stasevich; Nikoletta Vrcelj; Tracy Chaplin; Debra M Lillington; T Andrew Lister; Bryan D Young
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

5.  High-resolution genomic profiling of human papillomavirus-associated vulval neoplasia.

Authors:  K J Purdie; C A Harwood; K Gibbon; T Chaplin; B D Young; J B Cazier; N Singh; I M Leigh; C M Proby
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

6.  Single nucleotide polymorphism array analysis defines a specific genetic fingerprint for well-differentiated cutaneous SCCs.

Authors:  Karin J Purdie; Catherine A Harwood; Abha Gulati; Tracy Chaplin; Sally R Lambert; Rino Cerio; Gavin P Kelly; Jean-Baptiste Cazier; Bryan D Young; Irene M Leigh; Charlotte M Proby
Journal:  J Invest Dermatol       Date:  2009-01-08       Impact factor: 8.551

7.  Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia.

Authors:  Manu Gupta; Manoj Raghavan; Rosemary E Gale; Claude Chelala; Christopher Allen; Gael Molloy; Tracy Chaplin; David C Linch; Jean-Baptiste Cazier; Bryan D Young
Journal:  Genes Chromosomes Cancer       Date:  2008-09       Impact factor: 5.006

8.  Acquired mutations in TET2 are common in myelodysplastic syndromes.

Authors:  Saskia M C Langemeijer; Roland P Kuiper; Marieke Berends; Ruth Knops; Mariam G Aslanyan; Marion Massop; Ellen Stevens-Linders; Patricia van Hoogen; Ad Geurts van Kessel; Reinier A P Raymakers; Eveline J Kamping; Gregor E Verhoef; Estelle Verburgh; Anne Hagemeijer; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

9.  Clonal evolution through loss of chromosomes and subsequent polyploidization in chondrosarcoma.

Authors:  Linda Olsson; Kajsa Paulsson; Judith V M G Bovée; Karolin H Nord
Journal:  PLoS One       Date:  2011-09-20       Impact factor: 3.240

10.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers.

Authors:  Craig H Mermel; Steven E Schumacher; Barbara Hill; Matthew L Meyerson; Rameen Beroukhim; Gad Getz
Journal:  Genome Biol       Date:  2011-04-28       Impact factor: 13.583

  10 in total
  8 in total

1.  Expanded molecular profiling of myxofibrosarcoma reveals potentially actionable targets.

Authors:  Ellen Heitzer; Sandra Sunitsch; Magdalena M Gilg; Birgit Lohberger; Beate Rinner; Karl Kashofer; Nicole Stündl; Peter Ulz; Joanna Szkandera; Andreas Leithner; Bernadette Liegl-Atzwanger
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

2.  Novel gene targets detected by genomic profiling in a consecutive series of 126 adults with acute lymphoblastic leukemia.

Authors:  Setareh Safavi; Markus Hansson; Karin Karlsson; Andrea Biloglav; Bertil Johansson; Kajsa Paulsson
Journal:  Haematologica       Date:  2014-09-26       Impact factor: 9.941

3.  Exploring chromosomal abnormalities and genetic changes in uterine smooth muscle tumors.

Authors:  Bernadette Liegl-Atzwanger; Ellen Heitzer; Karin Flicker; Stephanie Müller; Peter Ulz; Ozlen Saglam; Fattaneh Tavassoli; Mojgan Devouassoux-Shisheboran; Jochen Geigl; Farid Moinfar
Journal:  Mod Pathol       Date:  2016-07-01       Impact factor: 7.842

4.  Novel recurrent chromosomal aberrations detected in clonal plasma cells of light chain amyloidosis patients show potential adverse prognostic effect: first results from a genome-wide copy number array analysis.

Authors:  Martin Granzow; Ute Hegenbart; Katrin Hinderhofer; Dirk Hose; Anja Seckinger; Tilmann Bochtler; Kari Hemminki; Hartmut Goldschmidt; Stefan O Schönland; Anna Jauch
Journal:  Haematologica       Date:  2017-03-24       Impact factor: 9.941

5.  SNP-array lesions in core binding factor acute myeloid leukemia.

Authors:  Nicolas Duployez; Elise Boudry-Labis; Christophe Roumier; Nicolas Boissel; Arnaud Petit; Sandrine Geffroy; Nathalie Helevaut; Karine Celli-Lebras; Christine Terré; Odile Fenneteau; Wendy Cuccuini; Isabelle Luquet; Hélène Lapillonne; Catherine Lacombe; Pascale Cornillet; Norbert Ifrah; Hervé Dombret; Guy Leverger; Eric Jourdan; Claude Preudhomme
Journal:  Oncotarget       Date:  2018-01-08

6.  The dynamic range of circulating tumor DNA in metastatic breast cancer.

Authors:  Maryam Heidary; Martina Auer; Peter Ulz; Ellen Heitzer; Edgar Petru; Christin Gasch; Sabine Riethdorf; Oliver Mauermann; Ingrid Lafer; Gunda Pristauz; Sigurd Lax; Klaus Pantel; Jochen B Geigl; Michael R Speicher
Journal:  Breast Cancer Res       Date:  2014-08-09       Impact factor: 8.408

7.  Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.

Authors:  J-B Cazier; S R Rao; C M McLean; A K Walker; A L Walker; B J Wright; E E M Jaeger; C Kartsonaki; L Marsden; C Yau; C Camps; P Kaisaki; J Taylor; J W Catto; I P M Tomlinson; A E Kiltie; F C Hamdy
Journal:  Nat Commun       Date:  2014-04-29       Impact factor: 14.919

8.  Whole-genome plasma sequencing reveals focal amplifications as a driving force in metastatic prostate cancer.

Authors:  Peter Ulz; Jelena Belic; Ricarda Graf; Martina Auer; Ingrid Lafer; Katja Fischereder; Gerald Webersinke; Karl Pummer; Herbert Augustin; Martin Pichler; Gerald Hoefler; Thomas Bauernhofer; Jochen B Geigl; Ellen Heitzer; Michael R Speicher
Journal:  Nat Commun       Date:  2016-06-22       Impact factor: 17.694

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.